Skip to content

Processa Pharmaceuticals, Inc.

Public company
Headquarters
VERO BEACH, Florida
Ticker
PCSA
CIK
0001533743

WARN notices since 2024

0
None on record

Workers affected since 2024

0
Across 0 notices

Executive changes, last 12 months

7
7 appointments, 0 departures

Last event

Nov 4, 2026
Executive appointmentCOO appointed: Gregory J. Flesher

Workers affected over time

Cumulative workers in WARN notices since 2024

Not enough notices to chart yet.

Leadership

Role and personSinceChange
COOGregory J. FlesherNov 4, 2026Appointed
directorJustin YorkeAug 4, 2026Appointed

Related companies

Same industry and state, with recent events.

  1. Executive appointment

    COO appointed: Gregory J. Flesher

    Gregory J. Flesher was named Chief Operating Officer of Processa Pharmaceuticals, Inc., effective November 4, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Operating Officer

    Source: SEC 8-K, filed Nov 4, 2026

  2. Executive appointment

    director appointed: Justin Yorke

    Justin Yorke was named director of Processa Pharmaceuticals, Inc., effective July 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: director

    Source: SEC 8-K, filed Aug 4, 2026

  3. Executive appointment

    director appointed: George Ng

    George Ng was named director of Processa Pharmaceuticals, Inc., effective July 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: director

    Source: SEC 8-K, filed Aug 4, 2026

  4. Executive appointment

    director appointed: Khoso Baluch

    Khoso Baluch was named director of Processa Pharmaceuticals, Inc., effective July 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: director

    Source: SEC 8-K, filed Aug 4, 2026

  5. Executive appointment

    director appointed: James Neal

    James Neal was named director of Processa Pharmaceuticals, Inc., effective July 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: director

    Source: SEC 8-K, filed Aug 4, 2026

  6. Executive appointment

    director appointed: Geraldine Pannu

    Geraldine Pannu was named director of Processa Pharmaceuticals, Inc., effective July 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: director

    Source: SEC 8-K, filed Aug 4, 2026

  7. Executive appointment

    director appointed: Dr, David Young

    Dr, David Young was named director of Processa Pharmaceuticals, Inc., effective July 30, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: director

    Source: SEC 8-K, filed Aug 4, 2026

Last verified Nov 8, 2026